Breast tenderness during hormone replacement therapy may indicate cancer risk
October 13th, 2009 - 5:05 pm ICT by ANIWashington, Oct 13 (ANI): Women who develop tenderness in their breasts after using hormone replacement therapy are at an increased risk of developing breast cancer, say researchers.
However, it is still unknown why breast tenderness indicates increased cancer risk among women on estrogen plus progestin hormone replacement therapy.
“Is it because the hormone therapy is causing breast-tissue cells to multiply more rapidly, which causes breast tenderness and at the same time indicates increased cancer risk? We need to figure out what makes certain women more susceptible to developing breast tenderness during hormone therapy than other women,” said Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.
The researchers compared the daily use of oral conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg), or CEE+MPA, with the daily use of a placebo pill.
Among the women who did report breast tenderness at the beginning, the risk at one-year was about 1.26 times that of their counterparts on placebos.
Of the women who reported new-onset breast tenderness, 76.3 percent had been on the combination therapy.
Women in the combination therapy group who did not have breast tenderness at the outset but experienced new-onset tenderness at the first annual follow-up had a 48 percent higher risk of invasive breast cancer than their counterparts on combination therapy who did not have breast tenderness at the first-year follow-up.
The study is published in Archives of Internal Medicine. (ANI)
- Postmenopausal hormone therapy 'ups breast cancer risk' - Oct 20, 2010
- How progesterone and estrogen increase breast cancer risk - Jan 19, 2011
- Hormone therapy linked to increased breast cancer risk: Study - Aug 11, 2010
- Hormone therapies 'up breast cancer metastasis risk in post-menopausal women' - May 07, 2010
- Breast cancer risk varies among different progestins used in hormone replacement therapy - Aug 11, 2010
- Menopausal hormone therapy 'ups ovarian cancer risk' - Nov 10, 2010
- Hormone mix may cut breast cancer risk in menopausal women - Oct 20, 2009
- Estrogen alone can cut risk of breast cancer - Dec 10, 2010
- Estrogen therapy 'ups kidney stones risk' in postmenopausal women - Oct 12, 2010
- Drop in breast cancer rates linked to reduced hormone therapy - Dec 01, 2010
- HRT raises risk of kidney stones - Oct 13, 2010
- Estrogen not linked to lung cancer mortality in postmenopausal women - Aug 14, 2010
- Parsley could help in breast cancer treatment - May 10, 2011
- Hormone replacement therapy 'increases lung cancer risk' - Mar 04, 2010
- Female sex hormone regulates weight - Oct 20, 2011
Tags: archives of internal medicine, breast cancer, breast tenderness, breast tissue, cancer risk, clinical professor, combination therapy group, david geffen school, david geffen school of medicine, david geffen school of medicine at ucla, dr carolyn, general internal medicine, health services research, hormone replacement therapy, invasive breast cancer, medroxyprogesterone, medroxyprogesterone acetate, placebo pill, placebos, tissue cells